Neurology Central

Solanezumab fails to significantly slow cognitive decline – new data published

In the much-anticipated follow-up from Eli Lilly and Company’s (IN, USA) EXPEDITION3 trail, data have published reporting that solanezumab did not significantly slow cognitive decline in patients with mild dementia due to Alzheimer’s disease (AD).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment